

Bruna Pellini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7611308/publications.pdf>

Version: 2024-02-01

17
papers

318
citations

1040056

9
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

291
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. <i>Journal of Clinical Oncology</i> , 2022, 40, 567-575. | 1.6 | 83 |
| 2 | Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127. | 3.8 | 67 |
| 3 | ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388. | 3.0 | 26 |
| 4 | The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 589-592. | 4.7 | 22 |
| 5 | Systemic therapy in primary angiosarcoma of the spleen. <i>Rare Tumors</i> , 2012, 4, 178-180. | 0.6 | 19 |
| 6 | Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 165-177. | 1.0 | 19 |
| 7 | Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 757-774. | 3.8 | 16 |
| 8 | Expression of cancer stem cell markers in basal and penta-negative breast carcinomas – A study of a series of triple-negative tumors. <i>Pathology Research and Practice</i> , 2014, 210, 432-439. | 2.3 | 14 |
| 9 | Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide. <i>American Journal of the Medical Sciences</i> , 2017, 353, 610-612. | 1.1 | 10 |
| 10 | A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062. | 1.4 | 9 |
| 11 | Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588. | 2.0 | 8 |
| 12 | Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. <i>JCO Precision Oncology</i> , 2020, 4, 806-817. | 3.0 | 7 |
| 13 | Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. <i>Cancers</i> , 2021, 13, 5611. | 3.7 | 7 |
| 14 | Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1104-1120. | 3.0 | 7 |
| 15 | Claudins 1, 3, 4, 7 and 10-year survival in triple-negative breast tumors. <i>Mastology</i> , 2019, 29, 71-78. | 0.1 | 2 |
| 16 | Predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP).. <i>Journal of Clinical Oncology</i> , 2015, 33, e17065-e17065. | 1.6 | 1 |
| 17 | Urinary cell-free DNA analysis for tumor mutation detection in patients with oligometastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15545-e15545. | 1.6 | 1 |